Physician profile
Ryan Kaye
NPI 1255783767
$3,749.07
in general payments reported to CMS, 2019-2025
3 companies · $649 in 2025
The $649 reported for 2025 was more than what 85% of Periodontics providers received nationally (typical 2025 total: $111).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $676 · 2024: $2,424 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Entertainment: $3,356 · Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Entertainment | $3,356.48 |
| Food and Beverage | $392.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Keystone Dental INC. | $3,616.34 | 2023-2025 | |
| Biolase, INC. | $118.34 | 2023 | Waterlase Iplus |
| Philips North America LLC | $14.39 | 2024 | (E55) Oral Health Care Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.